Diagnosis and management of acute coronary syndrome: An evidence-based update

Journal of the American Board of Family Medicine

Volumn 28, Issue 2, 2015, Pages 283-293

  Smith, Jennifer N ^a,d   Negrelli, Jenna M ^a,e   Manek, Megha B ^b   Hawes, Emily M ^a   Viera, Anthony J ^c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b GUTHRIE RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF THE SCIENCES   (United States)

^e INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Cardiology; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRASUGREL; TICAGRELOR; TROPONIN I; TROPONIN T; VORAPAXAR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTICOAGULANT THERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; ECG ABNORMALITY; EVIDENCE BASED PRACTICE; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL HISTORY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; PROCEDURES;

ACUTE CORONARY SYNDROME; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84928993343     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2015.02.140189     Document Type: Review

References (46)

1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-2035.
2. Anderson JL, Adams AD, Antman SM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiogradoi: phy and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-e304.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-e140.
4. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: A report from the American Heart Association. Circulation 2013;127:e6-e245.
5. Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. The rational clinical examination. Is this patient having a myocardial infarction? JAMA 1998;280:1256-1263.
6. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-867.
7. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006;92:987-993.
8. Balk EM, Ioannidis JP, Salem D, Chew PW, Lau J. Accuracy of biomarkers to diagnose acute cardiac ischemia in the emergency department: A meta-analysis. Ann Emerg Med 2001;37:478-494.
9. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med. 1998;31:3-11.
10. Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: A systematic review and meta-analysis. Ann Intern Med 2013;158:261-270.
11. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of unstable angina/non-ST segment myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol. 2012;60:645-681.
12. Cheng JW. Updates in antiplatelet agents used in cardiovascular diseases. J Cardiovasc Pharmacol Ther 2013;18:514-524.
13. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENTOASIS 7): A randomised factorial trial. Lancet 2010;376:1233-1243.
14. Sanofi Aventis. Clopidogrel (Plavix) package insert. Bridgewater NJ; 2013.
15. Eli Lilly and Company. Prasugrel (Effient) package insert. Indianapolis, IN; 2009.
16. Astra Zeneca LP. Ticagrelor (Brilinta) package insert. Wilmington, DE; 2011.
17. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
18. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
19. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;357:1045-1057.
20. Merck and Co, Inc. Vorapaxar (Zontivity) package insert. Whitehouse Station NJ; 2014.
21. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-1413.
22. Ganetsky VS, Hadley DE, Thomas TF. Role of Novel and Emerging Oral Anticoagulants for Secondary Prevention of Acute Coronary Syndromes. Pharmacotherapy. 2014;34:590-604.
23. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006;27:519-526.
24. Bristol-Myers Squibb. Warfarin (Coumadin) package insert. Princeton NJ; 1954.
25. Boehringer Ingelheim Pharmaceuticals, Inc. Dabigatran (Pradaxa) package insert. Ridgefield CT; 2010.
26. Janssen Pharmaceuticals, Inc. Rivaroxaban (Xarelto) package insert. Titusville NJ; 2011.
27. Bristol-Myer Squibb. Apixaban (Eliquis) package insert. Princeton NJ; 2012.
28. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-2789.
29. Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients stabilized after an ST-elevation myocardial infarction: Results from the ATLAS ACS 2-TIMI 51 trial. J Am Coll Cardiol 2013;61:853-859.
30. Johnson & Johnson. FDA issues complete response letters for use of XARELTO (rivaroxaban) to reduce the risk of secondary cardiovascular events and stent thrombosis in patients with acute coronary syndrome [press release]. February 14, 2014.
31. Bayer Healthcare. Bayer's Xarelto approved in the EU for secondary prevention after an acute coronary syndrome [press release]. May 24, 2013. Available from http://press.health.care/bayer.com/en/press/news-details-page.php/15050/2013-0292. Accessed April 18, 2014.
32. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
33. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet. 2005;366:1607-1621.
34. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
35. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: When is it "ok" to discontinue? Curr Cardiol Rev. 2012;8:77-84.
36. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
37. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
38. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-685.
39. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343:1115-1122.
40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
41. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
42. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
43. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
44. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther 2001;15:79-87.
45. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
46. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.